# Rosiglitazone Plaque Study

> **NCT00123227** · PHASE3 · UNKNOWN · sponsor: **Royal Brompton & Harefield NHS Foundation Trust** · enrollment: 60 (—)

## Conditions studied

- Diabetes Mellitus, Type 2
- Vascular Diseases
- Hypertension

## Interventions

- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT00123227
- **Lead sponsor:** Royal Brompton & Harefield NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123227, "Rosiglitazone Plaque Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00123227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*